Repligen Corp. (NASDAQ:RGEN) CEO Anthony Hunt sold 5,000 shares of Repligen Corp. stock in a transaction on Monday, November 28th. The stock was sold at an average price of $33.12, for a total transaction of $165,600.00. Following the completion of the sale, the chief executive officer now owns 68,342 shares of the company’s stock, valued at approximately $2,263,487.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Repligen Corp. (NASDAQ:RGEN) opened at 32.20 on Thursday. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 155.56 and a beta of 1.63. The company has a 50 day moving average of $30.24 and a 200-day moving average of $28.71. Repligen Corp. has a 52 week low of $20.07 and a 52 week high of $34.06.

Repligen Corp. (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 3rd. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. Repligen Corp. had a return on equity of 10.16% and a net margin of 6.89%. The firm had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.39 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The firm’s revenue was up 24.7% on a year-over-year basis. On average, equities research analysts expect that Repligen Corp. will post $0.45 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Anthony Hunt Sells 5,000 Shares of Repligen Corp. (RGEN) Stock” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of US & international copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/12/01/anthony-hunt-sells-5000-shares-of-repligen-corp-rgen-stock.html.

A number of institutional investors have recently added to or reduced their stakes in RGEN. TimesSquare Capital Management LLC purchased a new position in Repligen Corp. during the third quarter worth approximately $42,351,000. William Blair Investment Management LLC increased its position in Repligen Corp. by 179.0% in the second quarter. William Blair Investment Management LLC now owns 796,944 shares of the company’s stock worth $21,804,000 after buying an additional 511,296 shares in the last quarter. Kalmar Investments Inc. DE increased its position in Repligen Corp. by 60.3% in the third quarter. Kalmar Investments Inc. DE now owns 661,607 shares of the company’s stock worth $19,974,000 after buying an additional 248,929 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in Repligen Corp. during the second quarter worth approximately $5,741,000. Finally, Columbia Wanger Asset Management LLC increased its position in Repligen Corp. by 32.5% in the second quarter. Columbia Wanger Asset Management LLC now owns 800,877 shares of the company’s stock worth $21,912,000 after buying an additional 196,242 shares in the last quarter. Hedge funds and other institutional investors own 94.43% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of Repligen Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 11th.

About Repligen Corp.

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

5 Day Chart for NASDAQ:RGEN

Receive News & Stock Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related stocks with our FREE daily email newsletter.